INDIA LIVE DESKNIFTY 50:23,140.50(+0.34%)SENSEX:73,895.74(+0.43%)
RDU Global
๐Ÿ‡ฎ๐Ÿ‡ณ
Home/Topics/Companies & Institutions/Novartis
Back to Newsroom
๐ŸขOrganization Dossier

Novartis

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

2 Stories Indexed
Last Updated: Just Now
Verified Entity Intelligence
Global Markets & Equities 28 Oct 2026, 05:00 PM IST

Novartis Stands by Avidity Deal After $1.9 Billion Del-desiran Setback

Novartis is absorbing a steep charge after the failure of del-desiran, but management is signaling that the setback does not alter its confidence in the broader Avidity transaction. The company also lifted its annual profit guidance, underscoring a message of operational resilience even as clinical-trial volatility weighs on near-term earnings. Investors are now weighing whether Novartis can keep executing its pipeline strategy while defending the long-term case for external innovation.

By RDU Global Wire5 min read
Global Health & Biotech04 Oct 2026, 08:22 AM IST

Novartis Agrees to Up to $7.8 Billion mRNA Deal With Chinaโ€™s Abogen

Novartis has struck a licensing and development agreement with Chinese biotech Abogen Biosciences that could be worth as much as $7.8 billion, underscoring the Swiss drugmakerโ€™s push into next-generation cancer therapies. The deal centers on an mRNA-encoded T-cell engager, a highly targeted approach that has drawn intense interest from large pharmaceutical companies seeking to replenish pipelines and deepen exposure to innovative Chinese science.

6 min readRead โ†’

๐Ÿข About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Novartis: